CALR and neoplasm: Following treatment, calreticulin exposure on the cell membrane peaked at 6 h, and the levels of ATP and HMGB1 increased significantly (27, 35), indicating that combination therapy induces immunogenic cell death, thereby inhibiting tumor recurrence and metastasis.